Response Genetics, Inc
1640 Marengo Street
6th Floor
Los Angeles,
CA 90033
United States - Map
Phone: 323-224-3900
Fax: 323-224-3096
Web Site: http://www.responsegenetics.com
| Response Genetics, Inc., a life sciences company, engages in the research, development, marketing, and sale of clinical diagnostics and pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and Japan. It offers ResponseDX: Lung test suite, which comprises KRAS Mutation and EGFR Amplification tests. The KRAS Mutation test identifies tumors that have low probability of response to EGFR-directed therapy. The EGFR Amplification test assesses the probability of benefit from EGFR-directed therapy. The company also offers ResponseDX: Colon test suite that includes ERCC1, KRAS Mutation, and TS tests. The ERCC1 test is a test for the probability of response to platin-based therapies and the analysis of RRM1 tests for the probability of response to gemcitabine-based therapies. The TS test measures the probability of response to 5-fluorouracil -based chemotherapy. In addition, Response Genetics, Inc. is developing tests of other types of cancer that identify genetic profiles of tumors that recur after surgery. The company has collaboration agreements with Shanghai BioChip Company, Ltd. to provide pharmacogenomic testing services in China using the companys RGI-1 extraction technology; and Hitachi Chemical Co., Ltd. to use its techniques to extract genetic information from formalin-fixed paraffin-embedded tissue samples. It offers its services in the areas of oncology for oncologists, hospitals, and physician offices through the sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in 2000. The company was founded in 1999 and is headquartered in Los Angeles, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Ms. Kathleen Danenberg , 62
Chief Exec. Officer, Pres |
$
371.00K | N/A | Mr. Thomas Stankovich , 48
Chief Financial Officer, Principal Accounting Officer, VP and Sec. |
$
233.00K | N/A | Ms. Denise McNairn , 41
VP and Gen. Counsel |
$
238.00K | N/A | Dr. David M. Jackson Ph.D.,
Exec. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.67% Nasdaq 
0.02 (1.55%) 
Profile
